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1991Prevalence of Silent Cerebral Ischemia in Paroxysmal and
Persistent Atrial Fibrillation and Correlation With Cognitive FunctionObjectives The aim of this study was to compare the prevalence of silent cerebral ischemia (SCI) and cognitive performance
in patients with paroxysmal and persistent atrial ﬁbrillation (AF) and controls in sinus rhythm.Background Large registries have reported a similar risk for symptomatic stroke in both paroxysmal and persistent AF.
The relationship among paroxysmal and persistent AF, SCI, and cognitive impairment has remained uncharted.Methods Two hundred seventy subjects were enrolled: 180 patients with AF (50% paroxysmal and 50% persistent) and
90 controls. All subjects underwent clinical assessment, neurological examination, cerebral magnetic resonance,
and the Repeatable Battery for the Assessment of Neuropsychological Status.Results At least 1 area of SCI was present in 80 patients (89%) with paroxysmal AF, 83 (92%) with persistent AF
(paroxysmal vs. persistent, p ¼ 0.59), and 41 (46%) controls (paroxysmal vs. controls and persistent vs. controls,
p < 0.01). The number of areas of SCI per subject was higher in patients with persistent AF than in those with
paroxysmal AF (41.1  28.0 vs. 33.2  22.8, p ¼ 0.04), with controls reporting lower ﬁgures (12.0  26.7,
p < 0.01 for both). Cognitive performance was signiﬁcantly worse in patients with persistent and paroxysmal
AF than in controls (Repeatable Battery for the Assessment of Neuropsychological Status scores 82.9  11.5,
86.2  13.8, and 92.4  15.4 points, respectively, p < 0.01).Conclusions Patients with paroxysmal and persistent AF had a higher prevalence and number of areas of SCI per patient
than controls and worse cognitive performance than subjects in sinus rhythm. (J Am Coll Cardiol 2013;62:1990–7)
ª 2013 by the American College of Cardiology FoundationAtrial ﬁbrillation (AF) is known to relate, independently of
the presence of other comorbidities, to enhanced mortality
and thromboembolism (1), particularly to the brain. To date,
large registries have reported a similar risk for symptomatic
stroke in both the paroxysmal and the persistent forms
of this arrhythmia (2–4). A recent clinical experience in
patients with acute cerebral infarctions suggested, however,
that patients with persistent AF have signiﬁcantly worse
short-term outcomes in both functional ability and survival
compared with those with paroxysmal AF (5).
If symptomatic brain damage is easily diagnosed, the
relationship between AF, both paroxysmal and persistent,
and silent cerebral ischemia (SCI) has remained uncharted.
The presence of SCI is of relevance, because it has been
associated with an increased occurrence of stroke (6) and the
development of cognitive impairment (7,8).
See page 1998
Few studies (9–13) have investigated the prevalence of
SCI in patients with AF. The limited sample sizes, retro-
spective designs, and heterogeneity of patients and tech-
niques (e.g. computed tomography vs. magnetic resonance
[MR]) involved in these studies explain the broad variations
reported, from 15% to 86%. In addition, assessment of the
relationship between paroxysmal and persistent AF and
cognitive decline has, to date, relied only on clinical data not
supported by cerebral imaging (14–17).The aims of the present study were to compare: 1) the
prevalence of SCI; and 2) the cognitive performance in
patients with paroxysmal and persistent nonvalvular AF and
in controls in sinus rhythm (SR), without histories of AF.
Methods
Study population. From November 2008 to September
2012, consecutive patients referred to our cardiology divi-
sion or cardiovascular prevention outpatient clinic were
screened to generate 3 groups of patients with paroxysmal
or persistent AF or without histories of AF, balanced for
age, sex, risk factors, and education level.
Exclusion criteria were valvular heart disease, acute coro-
nary syndrome <3 months before, previous transcatheter
ablation, pacemaker implantation or other MR contraindi-
cations, history of transient ischemic attack or stroke, auto-
immune diseases, inﬂammatory brain diseases, tumors,
severe hepatic disorders, severe chronic renal insufﬁciency,
and alcohol abuse.
All patients were screened using the Mini Mental State
Examination (18) and the Beck Depression Inventory (19) to
rule out dementia and depression. Participants with scores
24 points on the Mini Mental State Examination
and  10 on the Beck Depression Inventory were excluded.
A ﬂowchart reporting numbers and reasons for exclusion
of the screened cohort down to the ﬁnal study population is
shown in Figure 1.
The ﬁnal study population consisted of 270 subjects:
180 patients with AF (90 paroxysmal and 90 persistent)
Figure 1 Study Flowchart
Flowchart reporting numbers and re
RBANS ¼ Repeatable Battery for th
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1992and 90 controls in SR without
histories of AF. AF was deﬁned
paroxysmal if self-terminating
within 7 days and persistent if
at least 1 AF episode lasted
longer than 7 days, on the basis
of direct patient interview and/or
exhaustive medical record search.
All patients gave written in-
formed consent before enroll-
ment; the study was conducted in
accordance to the latest Declara-
tion of Helsinki and approved by
the local ethics committee.
Baseline evaluation. All screened
subjects underwent extensive clin-ical assessment, including medical history (targeted to AF
type and duration, presence of heart disease, and comor-
bidities), thromboembolic risk assessment (CHA2DS2-
VASc score, consisting of congestive heart failure or left
ventricular dysfunction, hypertension, age, diabetes, stroke
or transient ischemic attack, thromboembolism, and
vascular disease) (20), physical examination, and electro-
cardiography. Hypertension was deﬁned as blood pressure
140/90 mm Hg (grade 1 hypertension, 140/90 to
159/99 mm Hg; grade 2 hypertension, 160/100 to 179/
109 mm Hg) (21). Diabetes was deﬁned as glycosylated
hemoglobin 6.5% (22). Hypercholesterolemia was
considered in case of evidence of a total cholesterol levelasons of exclusion of the screened cohort down to th
e Assessment of Neuropsychological Status; TIA ¼ tr>240 mg/dl (23). Smoking was considered habitual if the
patient smoked at least 20 cigarettes a day for at least
1 year.
A standardized neurological examination, according to
the National Institutes of Health Stroke Scale, was per-
formed by a certiﬁed neurologist. In addition, all patients
underwent Doppler echocardiographic sonography to
exclude carotid and vertebrobasilar district morphologic
and/or functional damage (stenosis of the lumen 70%,
according to European Carotid Surgery Trial criteria, or
peak systolic ﬂow velocity >150 cm/s).
Cognitive performance. Cognitive function was assessed
by a certiﬁed neuropsychologist using the Repeatable Battery
for the Assessment of Neuropsychological Status (RBANS)
(24,25), exploring 5 domains: immediate memory, visual-
spatial abilities, language, attention, and delayed memory.
MR imaging. Cerebral images were obtained using an
8-channel head coil 1.5-T MR imaging system (Magnetom
Avanto; Siemens Healthcare, Erlangen, Germany). The
imaging protocol included a sagittal T1-weighted spin-echo
sequence (repetition time 400 ms, echo time 13 ms, slice
thickness 5 mm, ﬁeld of view 230 mm, matrix size
192  256), an axial T2-weighted ﬂuid-attenuated inversion
recovery (FLAIR) sequence (repetition time 8,500 ms, echo
time 112 ms, inversion time 2,500 ms, slice thickness 5 mm,
ﬁeld of view 240 mm, matrix size 154  256), and a diffu-
sion-weighted sequence (repetition time 3,200 ms, echo
time 99 ms, slice thickness 5 mm, ﬁeld of view 230 mm,
matrix size 128  128, bandwidth 1,502 Hz, gradiente ﬁnal study population. AF ¼ atrial ﬁbrillation; MR ¼ magnetic resonance;
ansient ischemic attack.
Table 1
Baseline Characteristics of Patients With AF and Controls Included in the
Final Study Population
Variable
Paroxysmal AF
(n ¼ 90)
Persistent AF
(n ¼ 90)
Controls
(n ¼ 90) p Value
Age (yrs) 58.6  10.2 61.2  10.9 59.7  13.1 0.31
Men 69 (76.7%) 72 (80%) 68 (75.6%) 0.76
Hypertension 46 (51.1%) 47 (52.2%) 45 (50%) 0.96
Grade 1 33 (36.7%) 28 (31.1%) 33 (36.7%) 0.66
Grade 2 13 (14.4%) 19 (21.1%) 12 (13.3%) 0.31
Medications 39 (43.3%) 41 (45.6%) 36 (40%) 0.75
Beta-blockers 33 (36.7%) 36 (40%) 27 (30%) 0.36
ACE inhibitors/ARBs 28 (31.1%) 28 (31.1%) 25 (27.8%) 0.85
Diabetes 5 (5.6%) 7 (7.8%) 5 (5.6%) 0.78
Heart disease 6 (6.7%) 9 (10%) 7 (7.8%) 0.71
Coronary artery disease 3 (3.3%) 3 (3.3%) 4 (4.4%) 0.90
Hypertrophic cardiomyopathy 1 (1.1%) 2 (2.2%) 1 (1.1%) 0.78
Hypokinetic cardiomyopathy 1 (1.1%) 3 (3.3%) 2 (2.2%) 0.60
Congenital heart disease 1 (1.1 %) 1 (1.1%) 0 (0%) 0.60
AF duration (months) 84.2  70.4 85.2  91.2 d 0.80
Time since persistent AF (mo) d 15  28 d
CHA2DS2-VASc score*
0 27 (30%) 24 (26.7%) d 0.74
1 34 (37.8%) 24 (26.7%) d 0.15
2 19 (21.1%) 22 (24.4%) d 0.72
>2 10 (11.1%) 20 (22.2%) d 0.07
Dyslipidemia 26 (28.9%) 21 (23.3%) 24 (26.7%) 0.69
Antiplatelet agents/OAC
OAC 39 (43.3%) 79 (87.8%) 0 (0%) <0.01
Aspirin 100 mg/day 34 (37.8%) 9 (10%) 11 (12.2%) <0.01
None 17 (18.9%) 2 (2.2%) 79 (87.8%) <0.01
Smoking habit 26 (28.9%) 26 (28.9%) 31 (34.4%) 0.65
Education levely 2.6  0.9 2.6  0.9 2.5  1.0 0.71
Values are mean  SD or counts (%). *The CHA2DS2-VASc score consists of congestive heart failure or left ventricular dysfunction, hypertension, age,
diabetes, stroke or transient ischemic attack, thromboembolism, and vascular disease. yEducation level: 1 ¼ up to 5 years, 2 ¼ up to 8 years, 3 ¼ up
to 13 years, 4 ¼ more than 13 years.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; OAC ¼ oral anticoagulation.
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1993strength 22 mT, duration of diffusion gradients 31 ms,
gradient separation 42 ms in 3 orthogonal directions, B value
1,000). For each diffusion-weighted sequence, the apparent
diffusion coefﬁcient map was obtained. All sequences were
centered on the axis deﬁned by a line passing between the
anterior and posterior cerebral commissures.
According to anatomic-pathological criteria (26), areas of
SCI were deﬁned as focal, sharply demarcated, regularly or
irregularly shaped areas hyperintense on T2-weighted
FLAIR images or isointense on T1-weighted images. T2-
weighted FLAIR images were used to differentiate gliotic
ischemic lesions smaller than 3 mm from perivascular
spaces and lacunae (hypointense on T2-weighted FLAIR
images) (27).
The presence of even only 1 lesion allocated the subject
within the SCI group. Each individual area of SCI was
recorded, and small lesions closely grouped together,
exclusively localized in the subcortical white matter of the
frontal lobe, were deﬁned as a “spotted pattern.”
All MR scans were independently analyzed by 2 neuro-
radiologists, blinded to clinical data; conﬂict was resolved by
common agreement referring to a third expert.Statistical analysis. Continuous variables, presented as
means and standard deviations, were compared by analysis of
variance and subgroup comparisons corrected using the post
hoc Bonferroni correction. Categorical variables, presented
as counts and percentages, were compared in cross-
tabulation tables using chi-square tests (with Yates correc-
tion as appropriate), and odds ratio (OR) with their 95%
conﬁdence intervals (CIs) were computed. A logistic
regression model was performed to determine the correlation
between SCI and potential confounders selected on uni-
variate analysis (p < 0.50). All analyses were performed
using SPSS for Windows version 18.0 (SPSS, Inc, Chicago,
Illinois), and p values <0.05 were considered statistically
signiﬁcant.
Results
Baseline characteristics of the ﬁnal patient population are
summarized in Table 1.
SCI. At least 1 area of SCI was present in 80 patients
(89%) with paroxysmal AF, 83 (92%) with persistent AF
(paroxysmal vs. persistent AF, p ¼ 0.59), and 41 (46%)
Figure 2 Results of Cognitive Function Evaluation
Graph and results of cognitive function evaluation assessed by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score in controls (triangles),
patients with paroxysmal (PRX) atrial ﬁbrillation (AF) (diamonds), and patients with persistent (PER) AF (squares).
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1994controls (paroxysmal vs. controls and persistent vs. controls,
p < 0.01).
Cerebral lesions were bilateral in 81 patients (90%) with
persistent AF and 80 (89%) with paroxysmal AF (p ¼ 1.00),
compared with 36 (40%) controls (paroxysmal vs. controls
and persistent vs. controls, p < 0.01). Areas of SCI were
cortical and subcortical in 75 (83%) and 77 (85%) patients
with paroxysmal AF, 79 (88%) and 82 (91%) with persistent
AF, and 19 (21%) and 44 (49%) controls, respectively
(paroxysmal vs. persistent, p ¼ 0.50 and p ¼ 0.35; patients
with AF vs. controls, p < 0.01).
The number of areas of SCI per subject was signiﬁcantly
higher in patients with persistent than those with parox-
ysmal AF (41.1  28.0 vs. 33.2  22.8, p ¼ 0.04). The
number of areas of SCI per subject was signiﬁcantly higher
in patients with paroxysmal and persistent AF than in
controls, reporting lower ﬁgures (12.0  26.7; paroxysmal
vs. controls and persistent vs. controls, p < 0.01). AF
showed a higher risk for SCI compared with subjects in SR
(OR: 11.2; 95% CI: 6 to 21; p < 0.01), whereas no
difference was found between the 2 different forms of the
arrhythmia (OR: 1.5; 95% CI: 0.5 to 4.1; p ¼ 0.61). On
multivariate analysis, adjusted for age, CHA2DS2-VASc
score, and antiplatelet or oral anticoagulation treatment, the
presence of AF was strongly independently related to the
presence of SCI (OR: 7.2; 95% CI: 2.3 to 22.3; p ¼ 0.001).
The prevalence of the spotted pattern in the frontal lobe
was more common in patients with persistent than thosewith paroxysmal AF (67% vs. 50%, p ¼ 0.03). In controls,
the presence of this patterns was negligible (1%).
Cognitive function. Cognitive performance, assessed by
the RBANS, was signiﬁcantly worse in patients with
persistent and paroxysmal AF than in controls: 82.9
 11.5, 86.2  13.8, and 92.4  15.4 points, respectively
(paroxysmal vs. persistent AF, p ¼ 0.08; paroxysmal and
persistent AF vs. controls, p < 0.01). Speciﬁcally, patients
with AF obtained lower mean scores than controls in
all explored domains: immediate memory, visual-spatial
abilities, language, attention, and delayed memory
(Fig. 2). Concerning AF type, patients with persistent AF
showed a trend toward lower RBANS scores, driven mainly
by signiﬁcantly worse visual-spatial abilities (84.8  14.8
vs. 89.9  18.2, p ¼ 0.04) compared with patients with the
paroxysmal form of the arrhythmia.
Among patients with AF, those with the frontal pattern
(58%) showed a trend toward a lower mean total score
compared with those without (82.9  12.0 vs. 86.5  15,
p ¼ 0.06). However, they scored signiﬁcantly lower on the
visual-spatial ability subtest compared with subjects without
this pattern (85.1  16.7 vs. 90.7  17, p ¼ 0.02).
Discussion
The present study is, to the best of our knowledge, the ﬁrst to
investigate the relationship between AF and cognitive decline
supported by speciﬁcally addressed cerebral MR imaging.
Figure 3 A Clinical Case
Brain magnetic resonance images of a 55-year-old man with paroxysmal atrial ﬁbrillation without other risk factors: axial ﬂuid-attenuated inversion recovery sequences
demonstrate multiple small hyperintense lesions at the subcortical level in both hemispheres. Clusters (arrows) of small lesions are visible in the left frontal and temporo-
parietal regions (A), in the left frontal lobe (B), and in the right frontal lobe (C).
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1995The major ﬁndings of this study are as follows: 1) patients
with AF (both paroxysmal and persistent) have a higher
prevalence but, most of all, number of areas of SCI per
subject compared with controls; 2) persistent AF relates to
more areas of SCI per subject compared with paroxysmal
AF; 3) patients with AF have worse cognitive performance
compared with controls; and 4) despite similar cognitive
function by the RBANS between patients with paroxysmal
and those with persistent AF, visual-spatial abilities were
worse in patients with persistent AF.
The incidence of clinical ischemic stroke has been re-
ported as up to 5-fold higher in patients with AF compared
with the general population (2,3,28). Similarly, the present
study, including subjects with homogenous cardiovascular
risk factors by study design, reported a higher risk for SCI in
patients with AF compared to subjects in SR.
The high prevalence of SCI in controls (46%), compared
with that reported in the general population (29,30), may
relate to the baseline characteristics of this group. Because
of their selection within patients referring to a cardio-
vascular prevention outpatient clinic, the control group
presented a moderate to high cardiovascular risk proﬁle.
Interestingly, the prevalence of SCI in subjects with a
similar cardiovascular risk proﬁle in previous experiences
ranges from 53% to 58%, similar to that reported in the
present study (12,13,31).
Besides the higher prevalence of SCI, by discriminating
individual lesions in each patient, we registered a larger
number of areas of SCI per person in patients with parox-
ysmal and persistent AF compared with controls.SCI may certainly have both ischemic and embolic
origins. The design of this study, comparing patients with
AF and non-AF controls with similar prevalence of classic
cardiovascular factors, should, however, permit a focus on
the excess due to AF-related embolic lesions. Emboli of
cardiac origin are generally smaller than those due to athe-
rothrombotic material and cause lesions widely distributed,
on both sides, of the brain (9,32,33). In contrast, emboli, for
instance of carotid artery origin, are usually larger and
damage the ipsilateral hemisphere. For these reasons, the
peculiar cerebral MR pattern described in 50% and 67% of
the patients with paroxysmal and persistent AF, respectively,
presenting small, sharply demarcated lesions, often in
clusters, with a bilateral distribution, prevalently in the
frontal lobe, strongly supports an embolic mechanisms
(Fig. 3). This pattern is in fact clearly distinguishable from
atherosclerotic damage ipsilateral to a vascular lesion. In our
opinion, the spotted pattern described in this study may
derive from microembolization of multiple small platelet
thrombi in the terminal brain vessels (especially the lep-
tomeningeal arteries).
Furthermore, although patients with paroxysmal and
persistent AF did not present differences in SCI prevalence,
those with persistent AF showed a larger number of lesions.
To date, persistent and paroxysmal AF have been considered
to present similar stroke risk (2–4), and studies of symp-
tomatic cerebral damage rarely differentiate between the 2
clinical forms of the arrhythmia.
This result might be related to the longer presence and
duration of AF in the persistent form, causing a greater
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1996exposure time to AF-related thromboembolic etiology.
Considering the high clinical impact this ﬁnding may
provide, it surely warrants further conﬁrmation.
As shown in Table 1, patients with paroxysmal AF were
more commonly prescribed antiaggregant therapy compared
with those with persistent AF. This somewhat surprising
ﬁnding most likely is because patients were enrolled between
2008 and 2012. The evidence that aspirin is not beneﬁcial in
patients with AF ﬁrst emerged in 2011 (34). Before this
date, aspirin was commonly, although not on the basis of
evidence, chosen for treatment of patients with paroxysmal
episodes of AF.
As suggested by previous researches (16,17), AF relates to
cognitive decline; in particular, Santangeli et al. (17) found
that AF independently increases the risk for incident
dementia in elderly patients without acute stroke and in
those with normal baseline cognitive function.
Patients with AF performed worse in all investigated
cognitive domains compared with subjects without histories
of AF. Interestingly, the score difference highlighted
between patients with AF and controls relates to a relevant
clinical shift from medium to medium-low cognitive
performance (24). Although patients with persistent AF had
signiﬁcantly lower RBANS scores for visual-spatial abilities
compared with those with paroxysmal AF, no differences
were found in all other evaluated subtests. We would argue
that this might depend on the sensitivity of the neuro-
psychological test, which is capable of detecting only a few
types of cognitive deﬁcits within general cerebral function.
Visual-spatial abilities represent a cognitive function related
to the frontal subcortical cerebral circuits (35), which could
indeed be damaged by the presence, at this level, of the
spotted-pattern lesions. In conclusion, the anatomic brain
damage visible by MR did not remain, from a functional
point of view, truly “silent.” The present data suggest that
initially limited cerebral damage may become overt as the
number of cerebral lesions increases because of the persis-
tence of the arrhythmia.
Study limitations. The following general limitations apply
to this study. The cross-sectional study design investigating
time-dependent risks may represent a source of bias. Future
research on this topic should include longitudinal studies
with appropriate power and sample sizes. Furthermore, as in
most studies of this topic, an accurate measurement of the
effective period of anticoagulation or antiaggregant therapy
during exposure to the arrhythmia is lacking. For this reason,
any correlation between antiaggregant or anticoagulant
therapy and cerebral MR ﬁndings is avoided. Furthermore,
the neuropsychological test used in the present study is
a ﬁrst-level assessment tool, exploring only a limited selec-
tion of cognitive functions. We therefore cannot exclude
that the cognitive measures used may in certain cases
perform above the detection threshold. For these reasons,
the results of the present study are to be considered as
suggestive, not conclusive, for further research on this clin-
ically relevant topic.Conclusions
As for symptomatic strokes, patients with AF, both parox-
ysmal and persistent, have a higher prevalence of AF-related
SCI compared with controls in SR. Finally, patients with
AF were conﬁrmed to have worse cognitive performance
than subjects in SR.
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